Affordable Access

deepdyve-link
Publisher Website

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Authors
  • Voorhees, Peter M.1
  • Kaufman, Jonathan L.2
  • Laubach, Jacob3
  • Sborov, Douglas W.4
  • Reeves, Brandi5
  • Rodriguez, Cesar6
  • Chari, Ajai7
  • Silbermann, Rebecca8
  • Costa, Luciano J.9
  • Anderson, Larry D. Jr10
  • Nathwani, Nitya11
  • Shah, Nina12
  • Efebera, Yvonne A.13
  • Holstein, Sarah A.14
  • Costello, Caitlin15
  • Jakubowiak, Andrzej16
  • Wildes, Tanya M.17
  • Orlowski, Robert Z.18
  • Shain, Kenneth H.19
  • Cowan, Andrew J.20
  • And 9 more
  • 1 Levine Cancer Institute, Atrium Health, Charlotte, NC;
  • 2 Winship Cancer Institute, Emory University, Atlanta, GA;
  • 3 Dana-Farber Cancer Institute, Boston, MA;
  • 4 Huntsman Cancer Institute, School of Medicine, University of Utah, Salt Lake City, UT;
  • 5 Division of Hematology/Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC;
  • 6 Department of Hematology and Oncology, School of Medicine, Wake Forest University, Winston-Salem, NC;
  • 7 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;
  • 8 Knight Cancer Institute, Oregon Health & Science University, Portland, OR;
  • 9 University of Alabama at Birmingham, Birmingham, AL;
  • 10 Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX;
  • 11 Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA;
  • 12 Department of Medicine, University of California San Francisco, San Francisco, CA;
  • 13 The Ohio State University Comprehensive Cancer Center, Columbus, OH;
  • 14 Division of Oncology & Hematology, University of Nebraska Medical Center, Omaha, NE;
  • 15 Moores Cancer Center, University of California San Diego, La Jolla, CA;
  • 16 University of Chicago Medical Center, Chicago, IL;
  • 17 Section of Medical Oncology, Division of Oncology, School of Medicine, Washington University in St. Louis, St. Louis, MO;
  • 18 Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • 19 Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL;
  • 20 Division of Medical Oncology, University of Washington, Seattle, WA;
  • 21 Janssen Scientific Affairs, LLC, Horsham, PA;
  • 22 Janssen Research & Development, LLC, Titusville, NJ;
  • 23 Janssen Global Medical Affairs, Horsham, PA; and
  • 24 Janssen Research & Development, LLC, Leiden, The Netherlands
Type
Published Article
Journal
Blood
Publisher
American Society of Hematology
Publication Date
Aug 20, 2020
Volume
136
Issue
8
Pages
936–945
Identifiers
DOI: 10.1182/blood.2020005288
PMID: 32325490
PMCID: PMC7441167
Source
PubMed Central
License
Unknown
Report this publication

Statistics

Seen <100 times